Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01

被引：4

作者：

Johnson, M. L. ^{[1
]}

Janne, P. A. ^{[2
]}

Goto, Y. ^{[3
]}

Yoh, K. ^{[4
]}

Lee, S-H. ^{[5
,6
]}

Paz-Ares, L. ^{[7
]}

Besse, B. ^{[8
]}

Novello, S. ^{[9
]}

Hayashi, H. ^{[10
]}

Kim, D-W. ^{[11
,12
]}

John, T. ^{[13
]}

Kao, S. C-H. ^{[14
]}

Felip, E. ^{[15
,16
]}

Yang, J. C-H. ^{[17
]}

Reck, M. ^{[18
]}

Dong, Q. ^{[19
]}

Sporchia, A. ^{[19
]}

Sternberg, D. W. ^{[19
]}

Yu, H. A. ^{[20
]}

机构：

[1] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA

[2] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA

[3] Natl Canc Ctr Hosp, Thorac Oncol Dept, Chuo Ku, Chuo City, Japan

[4] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan

[5] Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea

[6] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul, South Korea

[7] Univ Complutense & Ciberonc, Hosp Univ 12 Octubre, Spanish Natl Canc Res Ctr, Madrid, Spain

[8] Univ Paris Saclay, Gustave Roussy, Villejuif, France

[9] Univ Turin, San Luigi Hosp Orbassano, Dept Oncol, Orbassano, Italy

[10] Kindai Univ, Dept Med Oncol, Osaka, Japan

[11] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul, South Korea

[12] Seoul Natl Univ Hosp, Seoul, South Korea

[13] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia

[14] Univ Sydney, Sydney Med Sch, Chris OBrien Life House, Sydney, NSW, Australia

[15] Vall dHebron Univ Hosp, Med Oncol Serv, Lung Canc Unit, Barcelona, Spain

[16] Vall dHebron Inst Oncol, Barcelona, Spain

[17] Natl Taiwan Univ Hosp, Dept Med Oncol, Taipei, Taiwan

[18] Airway Res Ctr North, German Ctr Lung Res, LungenClin, Grosshansdorf, Germany

[19] Daiichi Sankyo Inc, Oncol Clin Dev, Basking Ridge, NJ USA

[20] Mem Sloan Kettering Canc Ctr, Dept Med, Med Oncol, New York, NY USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2353

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1319MO

引用

页数：2

共 50 条

[1] HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC
Yu, Helena A.
Yang, James Chih-Hsin
Hayashi, Hidetoshi
Goto, Yasushi
Felip, Enriqueta
Reck, Martin
Vigliotti, Michele
Dong, Qian
Cantero, Frederique
Fan, Pang-Dian
Kanai, Masayuki
Sternberg, David W.
Jaenne, Pasi A.
FUTURE ONCOLOGY, 2023, 19 (19) : 1319 - 1329
[2] HERTHENA-Lung01: A randomized phase 2 study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC.
Janne, Pasi A.
Johnson, Melissa L.
Goto, Yasushi
Yang, James Chih-Hsin
Vigliotti, Michele
Dong, Qian
Qiu, Yang
Yu, Channing
Yu, Helena Alexandra
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[3] HERTHENA-Lung01: A Randomized Phase 2 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Previously Treated Metastatic EGFR-mutated NSCLC
Janne, P.
Johnson, M.
Goto, Y.
Yang, J. C.
Karam, S.
Chen, S.
Qiu, Y.
Yu, H.
Yu, C.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S236 - S236
[4] Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFRTKI and Platinum-Based Chemotherapy: HERTHENA-Lung01
Yu, H. A.
Goto, Y.
Hayashi, H.
Felip, E.
Yang, J. C. -H.
Reck, M.
Yoh, K.
Lee, S. -H.
Paz-Ares, L.
Besse, B.
Bironzo, P.
Kim, D. -W.
Johnson, M. L.
Wu, Y. -L.
Vigliotti, M.
Dong, Q.
Fan, P. -D.
Shrestha, P.
Sternberg, D. W.
Sellami, D.
Janne, P. A.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S53 - S54
[5] Dynamics of Molecular Markers in EGFR-Mutated NSCLC Patients Treated with Patritumab Deruxtecan (HER3-DXd; U3-1402)
Janne, P.
Baik, C.
Hayashi, H.
Su, W.
Qi, Z.
Enomoto, K.
Karnoub, M.
Yu, C.
Qiu, Y.
Yu, H. A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S237 - S237
[6] Phase 1 study of patritumab deruxtecan (HER3-DXd; U3-1402) in combination with osimertinib in patients with advanced EGFR-mutated NSCLC
Janne, Pasi A.
Mostillo, Joseph
Shrestha, Pomy
Zhang, Ruoyang
Fan, Pang-Dian
Cantero, Frederique
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[7] Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).
Janne, Pasi A.
Baik, Christina S.
Su, Wu-Chou
Johnson, Melissa Lynne
Hayashi, Hidetoshi
Nishio, Makoto
Kim, Dong-Wan
Koczywas, Marianna
Gold, Kathryn A.
Steuer, Conor Ernst
Murakami, Haruyasu
Yang, James Chih-Hsin
Kim, Sang-We
Vigliotti, Michele
Qi, Zhenhao
Qiu, Yang
Zhao, Lihui
Sternberg, David W.
Yu, Channing
Yu, Helena Alexandra
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[8] Pharmacokinetics, efficacy, and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
Yu, H. A.
Cantero, F.
Kim, B.
Lee, M.
Wu, E.
Sternberg, D. W.
Janne, P. A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1092 - S1093
[9] Phase 1 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Combination with Osimertinib in Patients with Locally Advanced or Metastatic EGFR-mutated NSCLC
Janne, P.
Rajagopalan, R.
Pudussery, G.
Shrestha, P.
Chen, S.
Hodge, R.
Qiu, Y.
Yu, C.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S237 - S237
[10] Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer
Janne, Pasi A.
Baik, Christina
Su, Wu-Chou
Johnson, Melissa L.
Hayashi, Hidetoshi
Nishio, Makoto
Kim, Dong-Wan
Koczywas, Marianna
Gold, Kathryn A.
Steuer, Conor E.
Murakami, Haruyasu
Yang, James Chih-Hsin
Kim, Sang-We
Vigliotti, Michele
Shi, Rong
Qi, Zhenhao
Qiu, Yang
Zhao, Lihui
Sternberg, David
Yu, Channing
Yu, Helena A.
CANCER DISCOVERY, 2022, 12 (01) : 74 - 89

← 1 2 3 4 5 →